Welcome To NeuRxs

Site is still under construction

BrainNeuRxS, Inc. was established and incorporated in 2008 to develop novel pharmaceutical and health products for the U.S. and global markets with an initial focus on a proprietary platform technology for transporting drugs across the Blood Brain Barrier (BBB) to ultimately treat a broad range of diseases of the brain. NeuRxS is headquartered in Rochester, Minnesota. Technology involving the targeted delivery of diagnostic and therapeutic agents is currently the cutting edge in the biosciences field. The basic premise of targeted delivery is of enhancing the effectiveness of therapeutic agents while also reducing adverse events or side effects of drugs. Current non-targeted drugs are toxic to normal healthy cells as well as the diseased cells they are intended to treat. The resulting toxicity of drugs can lead to suboptimal dosing thereby reducing the benefits of the drugs against the intended disease. According to the World Health Organization more than 1 billion people suffer from brain-related ailments and it is estimated that globally diseases of the brain cost approximately $2 trillion dollars to treat. Therapy for the many brain-related diseases is limited since drugs that may be beneficial for treatment are excluded or severely limited from entering the brain due to the blood brain barrier. The BBB protects the brain from influx of all but essential molecules. Because the Company's novel technology platform comprises positively charged modifications and amino acid substitutions which act as a natural gateway to the brain, many new and existing drugs, when joined with this technology, may be used to target previously difficult diseases of the brain. This represents a significant medical breakthrough with very broad application potential encompassing neurodegenerative diseases, brain cancers, depression, glaucoma, encephalitis and a variety of other disorders centered in the brain or in the central nervous system. The promise of broad product opportunities has allowed for the recruitment of an experienced management team with expertise in various areas of biotechnology product development which will oversee the further development of the technology and the commercialization of the various products.

Brain Tumor scan 

NeuRxs Drugs for Brain Tumors

In its protective role, the blood brain barrier prevents most drugs from reaching the brain and even those drugs that do penetrate the BBB rarely achieve therapeutically beneficial levelsat the treatment site. Because the Company's novel technology platform has demonstrated capabilities of effectively crossing that barrier and, more importantly, to cross that barrier carrying therapeutic drugs, new and existing drugs may be used to target previously inaccessible disease agents within the brain or the central nervous system. In contrast to currently approved drugs that address symptomatic aspects of various neurological diseases, we believe our technology platform (EnTransTM) and product pipeline may yield drugs that will provide true therapeutic benefit to patients with neurological disorders. In addition, we may be able to target diseases that previously have been untreatable (e.g. viral encephalitis). Our pipeline will first focus on modifying potent small molecule drugs for the treatment of brain cancers. These compounds have proven track records in cancer therapy, but have not been of general utility in brain tumors due to the inability to achieve cancer-destroying amounts of drug at the site of treatment. Secondary applications will be drug modifications to improve treatment of Parkinson's, depression and Alzheimer's disease. Ultimately, we will expand our focus to transporting antibody-based drugs and other biotherapeutics. Antibodies are a central factor in the body's immunity against invading pathogens, such as bacteria and viruses which can lead to encephalitis but antibodies are typically too large to cross the BBB, hence diseases like encephalitis are usually only treated with palliative measures. In summary, our technology will greatly expand treatment opportunities for diseases of the brain which previously were severely limited in treatment options.

Target: Parkinson's
 

Relevant Links

  • Blood Brain Barrier Information